Journal article
Targeted gene correction in the mdX mouse using short DNA fragments: towards application with bone marrow-derived cells for autologous remodeling of dystrophic muscle
RM Kapsa, AF Quigley, J Vadolas, K Steeper, PA Ioannou, E Byrne, AJ Kornberg
GENE THERAPY | NATURE PUBLISHING GROUP | Published : 2002
Abstract
In muscle, mutant genes can be targeted and corrected directly by intramuscular (i.m.) injection of corrective DNA, or by ex vivo delivery of DNA to myogenic cells, followed by cell transplantation. Short fragment homologous replacement (SFHR) has been used to repair the exon 23 nonsense transition at the Xp21.1 dys locus in cultured cells and also, directly in tibialis anterior from male mdx mice. Whilst mdx dys locus correction can be achieved in up to 20% of cells in culture, much lower efficiency is evident by i.m. injection. The major consideration for application of targeted gene correction to muscle is delivery throughout relevant tissues. Systemically injected bone marrow (BM)-derive..
View full abstract